Alentis Therapeutics AG
🇨ðŸ‡Switzerland
- Country
- 🇨ðŸ‡Switzerland
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.alentis.ch
Study of ALE.C04 in Patients With Head and Neck Cancer
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-09-26
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Alentis Therapeutics AG
- Target Recruit Count
- 220
- Registration Number
- NCT06054477
- Locations
- 🇫🇷
Centre Hospitalier Universitaire (CHU) de Bordeaux - Hospitalier Saint-Andre, Bordeaux, France
🇫🇷Oncopole Claudius Regaud, Iuct-Oncopole, Toulouse, France
🇪🇸Vall d'Hebron Institute of Oncology, Barcelona, Spain
Rescue of Nephrons With ALE.F02 (RENAL-F02)
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Alentis Therapeutics AG
- Target Recruit Count
- 80
- Registration Number
- NCT06047171
- Locations
- 🇩🇪
Universitaetsklinikum Schleswig-Holstein - Campus Luebeck, Luebeck, Germany
🇩🇪Klinikum der Ludwig-Maximilians-Universitaet Muenchen, München, Germany
🇪🇸Hospital Regional Universitario de Malaga, Malaga, Spain
A Clinical Trial of ALE.F02 in Patients With Advanced Liver Fibrosis and/or With Mild Cirrhosis
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2023-07-11
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Alentis Therapeutics AG
- Target Recruit Count
- 41
- Registration Number
- NCT05939947
- Locations
- 🇺🇸
American Research Corporation, San Antonio, Texas, United States
🇩🇪APEX GmbH, Munich, Germany
🇷🇴ARENSIA Exploratory Medicine S.R.L., Bucharest, Romania
© Copyright 2024. All Rights Reserved by MedPath